Literature DB >> 20093243

Analysis of von Willebrand factor multimers by simultaneous high- and low-resolution vertical SDS-agarose gel electrophoresis and Cy5-labeled antibody high-sensitivity fluorescence detection.

Helmut W Ott1, Andrea Griesmacher, Mirjam Schnapka-Koepf, Georg Golderer, Andrea Sieberer, Michael Spannagl, Burghardt Scheibe, Susanne Perkhofer, Kerstin Will, Ulrich Budde.   

Abstract

Analysis of von Willebrand factor (vWF) multimers allows classification of the subtypes of von Willebrand disease (vWD) in human serum and platelet lysates. A novel method for multimer analysis of vWF by 2-chamber, vertical (sodium dodecyl sulfate), agarose gel electrophoresis, designed for comparing discontinuous high- and low-resolving gels for plasma and platelets, followed by Western blotting and high-sensitivity fluorescence detection (HSFD) of cyanine (Cy)5-labeled vWF multimers is presented. HSFD shows that this method has high discriminatory power for visualization and densitometric analysis of platelets and plasma vWF multimers in various types of vWD and allows rapid classification of vWD types, to separate types 2A and 2B. The described procedures of vWF multimer analysis with high-sensitivity Cy5 fluorescence detection and direct comparison of high- and low-resolving gels for screening and detection of the complete range of high- and low-molecular vWF multimers is efficient and useful for screening, detecting, and classifying vWD subtypes and makes this method diagnostically and clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20093243     DOI: 10.1309/AJCPZSBTD2BWOMVL

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  6 in total

1.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

2.  Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura.

Authors:  Marie Scully; Paul Knöbl; Karim Kentouche; Lawrence Rice; Jerzy Windyga; Reinhard Schneppenheim; Johanna A Kremer Hovinga; Michiko Kajiwara; Yoshihiro Fujimura; Caterina Maggiore; Jennifer Doralt; Christopher Hibbard; Leah Martell; Bruce Ewenstein
Journal:  Blood       Date:  2017-09-14       Impact factor: 22.113

3.  von Willebrand factor propeptide variants lead to impaired storage and ER retention in patient-derived endothelial colony-forming cells.

Authors:  Mackenzie Bowman; Lara Casey; Soundarya N Selvam; Patricia D A Lima; Orla Rawley; Megan Hinds; Angie Tuttle; Julie Grabell; Alfonso Iorio; Irwin Walker; David Lillicrap; Paula James
Journal:  J Thromb Haemost       Date:  2022-05-03       Impact factor: 16.036

Review 4.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Authors:  Mike A Laffan; Will Lester; James S O'Donnell; Andrew Will; Robert Campbell Tait; Anne Goodeve; Carolyn M Millar; David M Keeling
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

5.  Flow-induced elongation of von Willebrand factor precedes tension-dependent activation.

Authors:  Hongxia Fu; Yan Jiang; Darren Yang; Friedrich Scheiflinger; Wesley P Wong; Timothy A Springer
Journal:  Nat Commun       Date:  2017-08-23       Impact factor: 14.919

6.  Characterization of Von Willebrand Factor Multimer Structure in Patients With Severe Aortic Stenosis.

Authors:  Joerg Kellermair; Helmut W Ott; Michael Spannagl; Josef Tomasits; Juergen Kammler; Hermann Blessberger; Christian Reiter; Clemens Steinwender
Journal:  Clin Appl Thromb Hemost       Date:  2017-12-04       Impact factor: 2.389

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.